Neurotransmitters and Toxicology / edited by Kevin Woodward and Tim Marrs.

Format:

Book

Contributor:

Woodward, Kevin, editor.

Marrs, Tim, editor.

Series:

Issues in toxicology ; Volume Volume 48.

Issues in Toxicology Series ; Volume Volume 48

Language:

English

Subjects (All):

Neurotransmitters.

Physical Description:

1 online resource (349 pages)

Edition:

First edition.

Place of Publication:

London, England : The Royal Society of Chemistry, [2024]

Summary:

Neurotransmitters and Toxicology will be particularly appealing to toxicologists interested in neurotoxicology in various sub-disciplines, as well as neuro-chemists interested in pathology and disease mechanisms associated with neurotoxicants.

Contents:

Cover

Neurotransmitters and Toxicology

Preface

Contents

Chapter 1: Introduction

1.1 The Evolution of Chemoception and Chemotransmission

1.2 Chemoception

1.3 The Evolution of Neurotransmitter Substances

1.4 The Evolution of Receptors

1.5 The Evolution of Synapses

1.6 Information Transfer in the CNS

1.7 Neuromodulation

1.8 Models of the Nervous System

References

Chapter 2: Cholinergic Neurotransmission

2.1 Introduction

2.1.1 Cholinergic Receptors

2.1.2 Cholinergic Agonists

2.1.3 Cholinesterases

2.2 Anticholinesterases

2.2.1 Introduction

2.2.2 Organophosphates

2.3 Carbamates

2.3.1 Introduction

2.3.2 Carbamate Pesticides

2.3.3 Carbamate Drugs

2.4 Cholinergic Antagonists

Chapter 3: Cholinergic Neurotransmission and Toxicity - Neonicotinoids and Spinosad

3.1 Neonicotinoid Mechanism of Action and Basis of Selectivity

3.2 Acetamiprid

3.2.1 Experimental Toxicity Data

3.2.2 Human Poisoning

3.3 Clothianidin

3.3.1 Experimental Data

3.3.2 Human Poisoning

3.4 Dinotefuran

3.4.1 Experimental Data

3.4.2 Human Poisoning

3.5 Imidacloprid

3.5.1 Experimental Data

3.5.2 Human Poisoning

3.6 Nitenpyram

3.6.1 Experimental Data

3.6.2 Human and Veterinary Poisoning

3.7 Thiacloprid

3.7.1 Experimental Data

3.7.2 Human Poisoning

3.8 Thiamethoxam

3.8.1 Experimental Data

3.8.2 Human Poisoning

3.9 Spinosad

3.9.1 Metabolism and Toxicokinetics

3.9.2 Acute Toxicity

3.9.3 Irritation and Sensitisation

3.9.4 Short-term Repeated-dose Toxicity

3.9.5 Chronic Toxicity and Carcinogenicity

3.9.6 Reproductive and Developmental Toxicity

3.9.7 Genetic Toxicity

3.9.8 Human Poisoning

Chapter 4: Glutamatergic Neurotransmission and Toxicity: Domoic Acid and Kainic Acid (Glutamic Acid Analogs).

4.1 Foundation of Glutamatergic Neurotransmission

4.1.1 Introduction

4.1.2 Mechanism of Glutamate Neurotransmission

4.1.3 Glutamate Receptor Nomenclature

4.1.4 Types of Glutamate Receptors

4.2 Glutamate Analogs: Kainic Acid and Domoic Acid

4.2.1 Introduction

4.2.2 Kainic Acid

4.2.3 Domoic Acid

4.2.4 Functionality of Kainic Acid and Domoic Acid

4.2.5 Other Glutamate Analogs: Dysiherbaine

4.2.6 An Ecological Perspective

4.2.7 Acute, High-level Exposure to Domoic Acid

4.2.8 Chronic, Low-level Exposure to Domoic Acid

4.3 Neurotoxicity

4.3.1 Excitotoxicity

4.3.2 Excitotoxicity and Epilepsy

4.3.3 Associated Neurological Features

4.3.4 Neural Plasticity

4.4 Applications and Models of Kainic Acid and Domoic Acid

4.4.1 The Silver Lining: Models of Epilepsy and Information on Neurological Mechanisms

4.4.2 Conclusions

Chapter 5: GABAergic Neurotransmission and Toxicity 1: Organochlorines

5.1 Introduction

5.2 General Toxicity Overview

5.2.1 Symptoms

5.2.2 GABAergic Transmission and Neurotoxicity

5.2.3 Hepatic Toxicity

5.2.4 Mutagenicity and Carcinogenicity

5.2.5 Reproductive, Endocrine Disruption and Development

5.2.6 Absorption, Distribution, Metabolism and Excretion

5.2.7 Human Exposures

5.3 Hexachlorocyclohexanes, Cyclodienes and Toxaphenes

5.3.1 Lindane and Other Hexachlorocyclohexanes

5.3.2 Chlorinated Cyclodienes

5.3.3 Toxaphene

5.3.4 Mirex and Chlordecone

5.4 Regulation

5.5 Summary

Chapter 6: GABAergic Neurotransmission and Toxicity 2: Macrocyclic Lactones

6.1 Introduction

6.2 Mode of Action

6.3 Toxicology

6.3.1 Acute Toxicity

6.3.2 Repeat-dose Toxicity

6.3.3 Other Studies

6.3.4 Overview of Toxicity

6.4 Factors Relating to Toxicity

6.5 Human Toxicity

6.6 Effects on Treated Animals.

6.6.1 Cats and Other Felids

6.6.2 Dogs

6.6.3 Equines

6.6.4 Cattle

6.6.5 Other Species

6.7 Conclusions

Chapter 8: GABAergic Neurotransmission and Toxicity 3: Isoxazolines

7.1 Introduction

7.2 Mode of Action

7.3 Safety in Veterinary Patients

7.4 Toxicology

7.5 Pharmacovigilance

7.5.1 Fluralaner

7.5.2 Afoxolaner

7.5.3 Sarolaner

7.5.4 Lotilaner

7.6 Conclusions

Chapter 8: Monoamine Neurotransmission and Toxicity

8.1 Monoaminergic System

8.1.1 Serotonin

8.1.2 Dopamine

8.1.3 Noradrenaline

8.1.4 Histamine

8.2 Mechanisms of Monoaminergic Neurotransmission Disruption

8.2.1 MN-synthesizing Enzyme Disruption

8.2.2 MN-metabolizing Enzyme Disruption

8.2.3 MN Transporter Disruption

8.2.4 MN Receptor Disruption

8.3 Monoamine Neurotransmitter Toxicity

8.3.1 MN Toxicity

8.3.2 Monoamine Neurotransmitter Metabolite Toxicity

8.4 Monoaminergic System Targets as Biomarkers of Toxicity

8.5 Conclusions

Chapter 9: Cannabinoid Neurotransmission: Neurotoxicity or Neuroprotection

9.1 Introduction

9.2 Endocannabinoid System

9.3 Cannabinoid Receptors: Distribution and Functions in the Brain

9.4 G-protein Coupling and Regulation of Signalling Pathways: Critical Determinant of Cannabinoid Roles in the Brain

9.5 Ageing, Brain Morphology and the Use of Cannabinoids: A Step Ahead of Neurodegeneration

9.6 Cannabinoids and Embryonic Exposure: Beginning of Susceptibility to Neurotoxicity

9.7 Cannabinoids and Neurogenesis: A New Way for Neuroprotective Role

9.8 Cannabinoids Neuroprotective or Neurotoxic: Choice of Therapeutic Implication

9.9 Cannabinoid Neurotransmission andNeurotoxicity

9.10 Cannabinoid Neurotransmission and Neuroprotection

9.11 Cannabinoids and Neurological Diseases.

9.11.1 Role of Cannabinoids in the Pathogenesis ofAlzheimer's Disease

9.11.2 Huntington's Disease and Cannabinoids

9.11.3 Cannabinoids and Their Role in Parkinson's Disease

9.11.4 Multiple Sclerosis and Cannabinoids

9.12 Neuropsychological Disorders and Cannabinoids

9.12.1 Schizophrenia

9.12.2 Anxiety and Depression and Use of Cannabinoids

Subject Index.

Notes:

Description based on publisher supplied metadata and other sources.

Description based on print version record.

Includes bibliographical references.

ISBN:

1-83916-580-4

1-83916-579-0